Unprecedented photolithographic structuring of novel light-sensitive poly(amino acid) materials– a paradigm shift in delivering biocompatible devices

Project Information

POLINA

Grant agreement ID: 101129842

DOI

10.3030/101129842

EC signature date 27 October 2023

Start date 1 January 2024

End date 31 December 2027

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 474 342,50

EU contribution

€ 3 474 342,50

Coordinated by

ROYAL COLLEGE OF SURGEONS IN IRELAND
Ireland

Periodic Reporting for period 1 - POLINA (Unprecedented photolithographic structuring of novel light-sensitive poly(amino acid) materials– a paradigm shift in delivering biocompatible devices)

Reporting period: 2024-01-01 to 2024-12-31

Summary of the context and overall objectives of the project

Over the past few decades, electronic devices have become smaller and more powerful, transforming modern life. A key technology behind this progress is photolithographic patterning, which uses light to create precise microscopic structures. The POLINA project aims to bring this technology into the medical field by developing a new type of light-sensitive material made from natural amino acids. This breakthrough could lead to the creation of advanced resins for 2D and 3D bioprinting for the design of safer medical devices that are more compatible with the human body, as well as eco-friendly electronics. POLINA is a high-risk, high-reward effort that combines cutting-edge materials with industrial techniques to revolutionise bioprinting and microfabrication. The project is expected to bring significant benefits to science, healthcare, and the environment, helping Europe remain a global leader in medical innovation. By replacing non-degradable materials with bio-inspired sustainable alternatives, POLINA also supports the Green Deal and a more environmentally friendly future.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

A set of new light-sensitive initiators that can be produced in sufficient quantity with high purity was achieved. Early tests show promising results in the light-driven formation of poly(amino acid)s (PAA) from the initiators. Adaptation of the polymerisation conditions allowed the production of special PAAs with controlled properties under both UV and visible light, in one instance achieving 99% conversion in just one minute. New resins with reactive side groups were also designed to create strong, photocurable materials. These resins were tested in 2D and 3D printing using light-based structuring techniques. The study helped validate the best approaches while identifying areas needing improvement. This work is a significant step toward developing advanced light-activated materials for use in biomedicine and sustainable manufacturing.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The successful photopolymerisation of poly(amino acid)s (PAAs) represents a major breakthrough in developing novel resins for 2D and 3D bioprinting. However, further research is needed to ensure seamless integration with existing printing technologies and to demonstrate the fabrication of well-defined 2D and 3D structures. Additionally, the design of printed structures must be tailored to meet clinical and commercial needs. If successful, this technology could unlock new opportunities for creating clinically relevant medical devices, such as implants, while also driving innovation in biomedical and bioengineering research. Beyond scientific advancements, market analysis and stakeholder feedback will be crucial in guiding the development and commercialisation of this promising technology.

POLINA team during the 1st General Assembly in San Sebastian

POLINA concept infographic